Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Cixutumumab |
| Trade Name | |
| Synonyms | IMC-A12 |
| Drug Descriptions |
Cixutumumab (IMC-A12) is an antibody against membrane-bound IGF-1R that prevents IGF-1 binding, inhibiting PI3K/AKT pathway activation and potentially leading to decreased tumor cell proliferation and increased tumor cell death (PMID: 29520435, PMID: 29909907). |
| DrugClasses | IGF1R Antibody 8 |
| CAS Registry Number | 947687-12-9 |
| NCIT ID | C79828 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Carboplatin + Cixutumumab + Paclitaxel | Bevacizumab Carboplatin Cixutumumab Paclitaxel | 0 | 0 |
| Cetuximab + Cixutumumab | Cetuximab Cixutumumab | 0 | 0 |
| Cixutumumab | Cixutumumab | 0 | 2 |
| Cixutumumab + Everolimus + Octreotide acetate | Cixutumumab Everolimus Octreotide acetate | 0 | 0 |